Visit our UK website
“I have received immaculate care and understanding”
The APOLLO E4 Study
The APOLLO E4 study aims to help slow the progression of Alzheimer’s disease with an investigational tablet delivered over the course of 18 months. To be screened for this Alzheimer’s-focused Research Study, we are looking for participants who meet the following criteria:
Qualifications:
- Ages of 50 to 80 years old
- Worried about your memory or have a diagnosis of early Alzheimer’s disease
- Want to be tested for the APOE4 gene
Relevant dates:
Always available – people can jump in at anytime
"*" indicates required fields
Benefits of attending
- Free, thorough health screening, including MRI scans & PET scans.
- Feel confidence in your health report with expert feedback & care at no extra cost
- Participate in low-stress & low-anxiety trial testing, including free genetic testing
- Volunteers get early access to new, advanced treatments for memory loss
- Travel expenses are reimbursed for each visit
-
-
“The range of tests, and the subsequent feedback, were so thorough and reassuring.”
-
“Without exception, all the staff are fantastic! Making you feel at ease. Nothing is too much trouble.”
About
Re:Cognition Health (RCH) opened as a private independent service provider in 2011, specializing in cognitive health. The company later expanded the scope of its services to include medical-legal and clinical research. It was founded by Dr. Emer MacSweeney, CEO (UK Citizen & resident) and Tom Dent, Chairman (USA Citizen & resident).
The portfolio currently includes 5 centers in the United Kingdom and 1 center in the USA. The first clinical trial center in the USA opened in May 2018. The USA portfolio has additional centers planned in 2020. Today Re:Cognition Health is recognized as the leading independent provider of Center services for cognitive disorders with successful award-winning business in:
- Adult acquired and progressive neuro-degenerative diseases
- Traumatic Brain injury –including medicolegal witness reporting and rehabilitation
- International Clinical Trials for Alzheimer’s Disease (AD) and other Central Nervous System (CNS) disorders